Triple-negative breast cancer (TNBC), defined by estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor receptor-2 (HER2)-negative histological presentation, accounts for approximately 20% of all breast cancer cases [2,3]. Here, ESR1 is linked to triple-negative breast carcinoma.